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ABSTRACT 
Objective: The purpose of present study was to formulate oral sustained release matrix tablet of metoclopramide hydrochloride and to evaluate the 
effect of varying concentrations of hydrophobic and hydrophilic polymers on drug release. 
Methods: Drug–excipients compatibility studies were carried out by using Fourier transform infrared spectroscopy (FTIR). The matrix tablets were 
prepared by direct compression technique using Xanthan gum and ethyl cellulose alone and in combination as release retardant. Dicalcium 
phosphate was used as diluent. The prepared matrix tablets were evaluated for their physicochemical parameters such as weight variation, 
hardness, friability, content uniformity and in vitro drug release studies were performed using USP-type II (paddle) dissolution apparatus. 
Results: Pre and post compression parameters were evaluated and all the parameters were found within the limit. The matrix tablets prepared 
with xanthan gum and combination of xanthan gum and ethyl cellulose were retarded the drug release upto 12 h. Ethyl cellulose alone could not 
control the drug release for 12 h. The Formulation with drug to xanthan gum (1:1.5), released 97.62 % of drug in 12 h. The kinetic treatment 
showed that the release of drug follows zero order kinetics (R 2
Conclusion: Matrix tablet is the simple, efficient and economic method to sustain the release of metoclopramide to prevent extrapyramidal side effects. 
=0.985). Korsmeyer and Peppas equation values of n were found to be in the range of 
0.40-0.56, indicating that the drug release mechanism was diffusion. 
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Metoclopramide hydrochloride is a potent antiemetic drug, used to 
treat emesis caused due to chemotherapy in cancer patients [1]. 
Metoclopramide is 4-amino-5-chloro-N-[2-(diethyl amino) ethyl 
amino) ethyl]-2-methoxy benzamide mono hydrochloride mono 
hydrate. It antagonizes D2
Oral administration is the most common and preferred route for 
delivery of most therapeutic agents. The popularity of oral route is 
attributed to ease of administration, accurate dosing, cost effective, 
flexibility in design of dosage form and high patient compliance. 
Sustained release dosage forms are designed to release the drug at a 
slow rate by maintaining a constant drug level in blood for a 
specified period of time with minimum side effects, optimized 
therapy and better patient compliance. Matrix technologies have 
often proven popular among the oral controlled drug delivery 
technologies because of their simplicity, ease in manufacturing, high 
level of reproducibility, stability of the raw materials, ease of scale-
up and process validation [6, 7]. In a Matrix system the drug is 
dispersed as solid particles within a porous matrix former of a 
hydrophilic or hydrophobic polymer [8]. Drug release in matrix 
tablets is controlled by the polymer properties and its structure. 
Natural gums are inert and non toxic. Xanthan gum is a natural, 
biosynthetic, edible gum, high molecular weightgum. Xanthan gum is 
an extracellular polysaccharide produced by fermentation of 
carbohydrate with Xanthomonas Compestris bacteria, is hydrophilic 
swellable polymer. It is a long chained polysaccharide with large 
number of tri saccharides side chains. The side chains are composed 
of two mannose units and one glucuronic acid unit. It develops a 
weak structure in water which creates high viscosity solutions at 
low concentration. Ethyl cellulose is hydrophobic synthetic polymer, 
is a derivative of cellulose [9, 10]. 
 dopamine receptors in chemoreceptor 
trigger zone (CTZ) of the medulla. It exerts gastroprokinetic (increases 
motility of the stomach and duodenum) effect by antagonizing 
dopamine mediated relaxation effect on gastro intestinal smooth 
muscle results to an increase of gastric empting into the intestine there 
by preventing nausea and vomiting. Metoclopramide hydrochloride is 
a freely soluble drug and is rapidly absorbed from the gastrointestinal 
tract [2, 3]. It has short and variable biological half-life i.e. 5±1 hr [4]. It 
is usually administered in per oral dose of 10-15 mg four times a day. 
This frequent administration results blood level fluctuations leads to 
extrapyramidal symptoms [5].  
The aim of this study was to prepare matrix tablets of 
metoclopramide hydrochloride using varying proportions of the 
xanthan gum and ethyl cellulose to achieve sustained release of 
drug. Sustained release of the drug would prevent the 
extrapyramidal side effects of the drug on the central nervous 
system and improve the patient compliance. The probable additive 
effect of mixture of xanthan gum and ethyl cellulose on retarding 
drug release was also studied. 
MATERIALS AND METHODS 
Materials 
Metoclopramide hydrochloride was purchased from Yarrow 
chemical Ltd., Mumbai (India). Xanthan gum, ethyl cellulose, 
dicalcium phosphate, magnesium stearate and talc were purchased 
from Aman scientific traders Vijayawada (India). All other reagents 
used were of analytical grade. 
Methods 
Analytical method for calibration curve of metoclopramide 
hydrochloride 
Maximum wavelength of metoclopramide hydrochloride was found 
to be 272 nm using UV-visible spectroscopy. Standard solution 
(100µg/ml) was prepared from stock solution (1 mg/ml) with pH 6.8 
phosphate buffer. Aliquotes of standard drug solution ranging from 
0.4 to 2.4 ml were transferred into 10 ml volumetric flask and were 
diluted up to the mark with pH 6.8 phosphate buffer. The absorbance 
of each solution was measured at 272 nm against pH 6.8 phosphate 
buffer. A plot of concentration of drug versus absorbance was 
plotted. The linear regression analysis was applied. The standard 
regression equation for metoclopramide hydrochloride obtained 
was y = 0.037x+0.003 with a coefficient of regression (R 2) of 0.999. 
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Drug-excipient compatibility study 
Compatibility study of metoclopramide hydrochloride with the 




Dose calculation of the sustained release formulation [11] 
 
Total dose = usual dose (D) + maintenance dose (Dm) 
 
Pharmacokinetic studies showed that a dose of 10 mg of 
metoclopramide hydrochloride produces an effective blood level 
concentration within 0.5 h with the mean half-life of 4 h. 
The elimination rate constant    
== 0.1732 h-1 
The available rate R= k x D 
= 0.1732 x 10 = 1.732 mg/h. 
Where, D is the usual dose of the drug. 
But D is corrected = D − (R x tp) = 10 − (1.732 x 0.5) = 9.134 mg.  
Where, tp is the time period required to achieve a peak plasma 
concentration. 
The maintenance dose, Dm = R x h 
    = 1.732 x 12 = 20.784 mg. 
Where, h is the number of hours for which sustained action is 
desired. 
Thus the total dose of the drug was calculated by the following 
equation  
Therefore total dose corrected = D corrected + Dm   
=9.134 +20.784 = 29.918 mg 
  Total dose corrected ≡ 30 mg 
Preparation of matrix tablets 
Matrix tablets of metoclopramide hydrochloride were prepared by 
direct compression technique. All the ingredients were individually 
screened through sieve no. 60, except glidant and lubricant. 
Required quantities of metoclopramide hydrochloride, polymer, 
diluent were accurately weighed according to the composition 
shown in table 1 and mixed in a polybag for about 30 to 45 min. The 
obtained blend was lubricated with talc and magnesium stearate for 
another 5 min and then the resultant mixture was directly 
compressed into tablets with 8 mm dome-shaped punches using 12-
station rotary tablet machine (CEMACH, Ahmedabad, India). The 
final weight of the tablet was adjusted to 250 mg. 
  
Table 1: Composition of matrix tablets of metoclopramide hydrochloride 
Ingridients per tablets (mg) Composition (mgs) of the prepared formulation 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Metoclopramide 30 30 30 30 30 30 30 30 30 
Xanthan gum (XG) 30 45 60 - - - - - - 
Ethyl cellulose (EC) - - - 30 45 60 - - - 
XG+EC - - - - - - 30 45 60 
Di calcium phosphate 180 165 150 180 165 150 180 165 150 
Magnesium stearate 5 5 5 5 5 5 5 5 5 
Talc 5 5 5 5 5 5 5 5 5 
Tablet weight 250 250 250 250 250 250 250 250 250 
 
Micromeritic properties of the blended powder  
Angle of repose  
The angle of repose of powder blend was determined by the fixed 
funnel method. The accurately weighed powder was taken in a 
funnel. The height of the funnel was adjusted in such a way that 
the tip of the funnel just touched the apex of the heap of the 
powder. The powder was allowed to flow through the funnel freely 
onto the surface. The diameter of the powder cone was measured 
and the angle of repose was calculated using the following 
equation [12]. 




Where, θ = angle of repose, 
h = height of the pile, 
r = radius of the pile base 
Bulk density and tapped density 
A quantity of 2 g of powder from each formula, previously lightly 
shaken to break any agglomerates formed was introduced into a 10 
ml measuring cylinder. After the initial volume was observed then 
calculate bulk density using the following formula [12]. 
Bulk density =
weight of the powder
bulk volume
 
The cylinder was allowed to fall under its own weight onto a 
hard surface from the height of 2.5 cm at 2-second intervals. The 
tapping was continued until no further change in volume was 
noted. Tapped density was calculated using the following 
formula [12]. 
tapped density =
weight of the powder
tapped volume
 
Compressibility index  
The compressibility index of the powder blend was determined by 
Carr’s compressibility index [12]. 
Carr′s index =
tapped density − bulk density
tapped density
× 100 
Evaluation of matrix tablets 
The tablets were evaluated for their physical properties like weight 
variation, hardness, and friability. 
Weight variation 
20 tablets of each formulation were weighed using an electronic 
weighing balance. The average weight was calculated and individual 
tablet weight was compared with average weight [12]. 
Hardness and friability 
The hardness of three tablets was measured by Monsanto hardness 
tester. Hardness of tablets was measured in terms of kg/cm 2
Uniformity of drug content 
 Friability 
of tablets was measured by using Roche friabilator. Ten tablets were 
accurately weighed and placed in the friabilator and operated for 100 
revolutions. The tablets were dedusted and reweighed and friability 
was calculated using the following equation [14]. 
Friability =
Initial weight − Final weight
Initial weight
× 100 
10 Tablets were weighed from each formulation and triturated in the 
mortar to a fine powder. Powder equivalent to 30 mg of metoclopramide 
was extracted in 100 ml of pH 6.8 phosphate buffer and the liquid was 
filtered. The drug content was determined by measuring the absorbance 
at 272 nm (using UV-Visible spectrophotometer, Lab India) after 
appropriate dilution with pH 6.8 phosphate buffer. The drug content was 
determined by calibration curve. 
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In vitro dissolution study 
The in vitro dissolution study of matrix tablets of metoclopramide 
was performed using USP type II (paddle) dissolution apparatus 
(DBK) at a rotational speed of 50 rpm. In order to simulate 
gastrointestinal transit conditions, the tablets were subjected to 
different dissolution media. The dissolution medium consists of 900 
ml of pH 1.2 buffer for the first two hours and pH 6.8 phosphate 
buffer for the next ten hours. The dissolution medium was 
maintained at a temperature of 37±0.5 ° C. At predetermined time 
intervals, 5 ml sample of the solution was withdrawn from the 
dissolution apparatus and the samples were replaced with fresh 
dissolution medium. The collected samples were filtered through a 
0.45 µm membrane filter and diluted to a suitable concentration 
with pH 6.8 phosphate buffer. An absorbance of these solutions was 
measured at 272 nm. Cumulative percentage of drug release was 
calculated using equation obtained from a calibration curve [15]. 
Kinetic analysis of drug release data 
The drug release data was fitted to zero order and first order to know 
the order of reaction. To study the mechanism of drug release from the 
formulations the release data were fitted to the following equations. 
Higuchi model: Q=KH t ½ 
Korsmeyer–Peppas model: Q/Q t =KKP
Where Q is amount of drug release at time t, Q 
 t n 
T is the total amount 
of drug release and n is the diffusional exponent that characterizes 
the mechanism of drug release. The values of the coefficient were 
calculated using the regression analysis between log Q/Q T and log 
time. The diffusional exponent n value was obtained from the slope 
of the regression equation and K KP
If the value of n for a cylinder is<0.45 it suggests the Fickian release 
(diffusion controlled), if n>0.45 and<0.89 it is non–Fickian release 
(diffusion and polymer relaxation), 0.89 is case II release (only 
relaxation and swelling) and>0.89 it suggests super case II release 
(relaxation and erosion) for swellable systems 
 was calculated from antilog of 
the intercept value. 
For cylindrical systems like tablets, the n values of 0.45 and 0.89 
represent pure diffusion or erosion release respectively [16]. 
RESULTS AND DISCUSSION 
Powder characterization  
The powder mixture of all the formulations were evaluated for angle 
of repose, bulk density, tapped density, compressibility index, and 
their values were shown in table 2. Angle of repose and 
compressibility index for all the formulations were found to be less 
than 30 ° and less than 17.13 %, indicated that powder mixture has 
good flow properties. 
  
Table 2: Micromeritic properties of formulation blends 
Formulation  Bulk density (gm/cm3 Tapped density (gm/cm)* 3 Compressibility index (%) )* Hausners ratio Angle of repose( °) 
F1 0.33±0.03 0.40±0.01 17.13 1.21 25.40 
F2 0.32±.03 0.39±0.02 17.81 1.22 24.26 
F3 0.35±0.01 0.40±0.02 12.50 1.14 26.15 
F4 0.31±0.03 0.37±0.03 16.22 1.19 26.82 
F5 0.32±0.02 0.39±0.03 17.18 1.21 28.30 
F6 0.31±0.01 0.38±0.02 17.63 1.21 25.34 
F7 0.35±0.03 0.40±0.03 14.11 1.16 28.18 
F8 0.32±0.01 0.38±0.02 15.00 1.18 28.24 
F9 0.34±0.03 0.42±0.02 17.38 1.21 27.82 
*
 
Evaluation of physical parameters 
All values are expressed as mean±SD, n=3  
Sustained release matrix tablets of metoclopramide hydrochloride 
were prepared by direct compression technique employing varying 
concentrations of xanthan gum (F1,F2, F3), ethyl cellulose (F4,F5,F6) 
and their mixture-xanthan gum plus ethyl cellulose (F7,F8, F9). All 
the tablets were found to be non-disintegrating in 0.1 N hydrochloric 
acid and pH 6.8 phosphate buffer except formulations prepared with 
ethyl cellulose. The physical properties of metoclopramide matrix 
tablets were given in table 3. In weight variation test the percentage 
deviation of all tablet formulations was found to be within the 
pharmacopoeial acceptable limit. The hardness of the tablets was 
found to be in the range of 5.05±0.15 to 5.87±0.08 kg/cm2
The percentage weight loss in the friability test was found to be 
below 1 % in all the cases indicated that all the tablets had good 
mechanical strength. The drug content in all the batches was 
measured by double beam UV spectrophotometer (LABINDIA). The 
content of metoclopramide hydrochloride was found to be in the 
range of 98.33 to 99.98%. 
.  
 
Table 3: Physical properties of metoclopramide hydrochloride matrix tablets 
Formulation Weight variation (mg) Hardness (kg/cm# 2) Friability (%) * Content uniformity (%) 
F1 248.80±1.40 5.63±0.08 0.48 99.80 
F2 248.95±1.57 5.87±0.08 0.40 98.64 
F3 249.10±1.62 5.98±0.14 0.36 99.66 
F4 248.95±1.56 5.05±0.15 0.68 99.98 
F5 249.05±1.61 5.13±0.12 0.64 99.05 
F6 248.15±1.46 5.20±0.14 0.61 98.33 
F7 249.15±1.57 5.52±0.08 0.52 98.92 
F8 249.15±1.50 5.73±0.08 0.52 98.43 
F9 248.70±1.38 5.80±0.09 0.48 98.68 
*
 
All values are expressed as mean±SD, #n=20; *n=6. 
In vitro dissolution study 
Metoclopramide release from the matrix tablets was studied for the 
first two hours in pH 1.2 buffer and the next ten hours in pH
Metoclopramide release from all the matrix tablets was 
dependent on the percent of release retardant contained in the 
tablet. As the percent of the polymer was increased, release was 
decreased. Ethyl cellulose could not control the release of 
metoclopramide from the tablets because when a matrix is 
composed of a water-soluble drug and a water-insoluble 
polymer, drug release occurs by dissolution of the active 
 6.8 
phosphate buffer. Total nine formulations were made with xanthan 
gum, ethyl cellulose and combination of xanthan gum and ethyl 
cellulose in different ratios i. e 1:1, 1:1.5 and 1:2. The release profiles 
are given in fig. 1.  
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ingredient through capillaries. Xanthan gum could control the 
release of metoclopramide hydrochloride up to 12 h because of 
its high molecular weight. These results indicate that xanthan 
gum has a higher drug retarding ability than ethyl cellulose. 
Presence of xanthan gum alone and in combination retarded the 
initial release of drug from the tablets due to high swelling.  
The release data of matrix tablets were fitted into various 
mathematical models (zero order, first order, higuchi, and 
Peppas) to evaluate the kinetics and mechanism of drug release 
from the tablets. The model that best fits the release data is 
selected based on the correlation coefficient value in various 
models. The model that gives high R2 value considered as the 
best fit of the release data. The R 2
 
values in zero, first order, 
higuchi peppas, and hixon-crowel models are given in table 4. 
Fig. 1: Comparative in vitro dissolution profile of all the 
formulations mean±SD, n=3
 
Table 4: Release kinetics of metoclopramide hydrochloride matrix tablets 
Formulation  Zero-order First order Higuchi  Peppas Hixon-crowel 
R n 2 
F1 0.894 0.975 0.989 0.989 0.43 0.883 
F2 0.923 0.897 0.993 0.991 0.52 0.956 
F3 0.963 0.985 0.987 0.990 0.56 0.990 
F4 0.853 0.946 0.992 0.999 0.40 0.977 
F5 0.888 0.973 0.986 0.982 0.40 0.862 
F6 0.920 0.860 0.988 0.981 0.46 0.938 
F7 0.945 0.847 0.993 0.986 0.53 0.943 
F8 0.918 0.872 0.994 0.995 0.48 0.948 
F9 0.927 0.904 0.995 0.996 0.50 0.961 
 
The results given in table 3 indicated that the drug release from the 
matrix tablets followed zero order kinetics. To evaluate the drug 
release mechanism from the matrix tablets plots of percent drug 
released verses square root of time as per Higuchi’s equation were 
constructed. These plots were found to be linear with all the tablets 
with correlation coefficient values in the range 0.986 to 0.995 
indicating that the drug release from the tablet was diffusion 
controlled. When the release data were analyzed as per peppas 
equation, the release exponent n value was less than 0.89 with all 
the tablets indicating Fickian diffusion might be the mechanism for 
the drug release from the matrix tablets. 
Compatibility studies 
From the FTIR studies shown in fig 2, it is very clear that there are 
no interactions between drug and excipients. All the peaks 
responsible for the active functional groups were present in the best 
formulation (F2). The characteristic and observed peaks are 
mentioned in table 5. 
 
 
Fig. 2(a): FTIR spectrum of pure metoclopramide hydrochloride 
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Fig. 2(b): FTIR spectrum of metoclopramide hydrochloride matrix tablet (F2) 
 
Table 5: Data of FT-IR spectra of pure and best formulation 
Functional group Characteristic peak cm- Observed peaks-pure drug cm-1 Observed peaks-best formulation cm-1 1 






OCH 1270-1230 3 1269 1268 
N-H (bending) 1650-1580 1596 1645 
C-N (stretching) 1220-1020 1215 1211 
C=C 1500 1501 1502 
 
CONCLUSION 
Sustained release matrix tablets of metoclopramide hydrochloride 
were prepared using different ratios of xanthan gum and ethyl 
cellulose by direct compression method. The results of the present 
study demonstrate that the ethyl cellulose alone could not control 
the metoclopramide release effectively for 12 h, whereas when 
combined with xanthan gum, it could control the release of 
metoclopramide from their matrices. It is concluded that the 
sustained release of metoclopramide hydrochloride over a period of 
12 h was obtained with formulation (F-2) containing xanthan gum. 
The mechanism of drug release from the matrix tablets was found to 
be diffusion controlled i. e fickian diffusion. Sustained release matrix 
tablets of metoclopramide hydrochloride can be expected to reduce 
the frequency of administration and decrease the dose-dependent 
side effects associated with repeated administration of conventional 
metoclopramide hydrochloride tablets. 
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